![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2017/11/OHC-Cancer-Immunotherapy-300x137.jpg)
Tumour immune rejection triggered by activation of α2-adrenergic receptors
Abstract Immunotherapy based on immunecheckpoint blockade (ICB) using antibodies induces rejection of tumours and brings clinical benefit in patients with various cancer types1. However, tumours